Seigo Nishida
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Seigo Nishida has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
- Kenji Okumura
Westchester Medical Center, Department of Surgery, Valhalla, New York
21 shared publications - Abhay Dhand
Department of Medicine, New York Medical College, Valhalla, NY
20 shared publications - Ryosuke Misawa
Department of Surgery, Westchester Medical Center and New York Medical College, Valhalla, New York
10 shared publications - Gregory Veillette
Department of Surgery, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
7 shared publications - Hiroshi Sogawa
Department of Surgery, Westchester Medical Center and New York Medical College, Valhalla, NY, USA
7 shared publications - Suguru Ohira
Department of Cardiac Surgery, Hartford Hospital, Hartford, CT, USA
7 shared publications
Latest Publications
- Open Access
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Successful Salvage of a Pancreas Allograft Following Duodenal and Partial Pancreatic Necrosis 21 Years After Simultaneous Pancreas-Kidney Transplantation: A Case Report
Simultaneous pancreas-kidney transplantation is an established treatment for type 1 diabetes mellitus and renal dysfunction. However, pancreatic graft complications frequently require graft pancreatectomy. This report describes successful salvage of a functioning pancreas allograft despite extensive duodenal and partial pancreatic necrosis occurring 21 years after transplantation.A 68-year-old man with a simultaneous pancreas-kidney transplant performed 21 years earlier presented with acute right lower quadrant abdominal pain, nausea, and vomiting. Laboratory evaluation revealed leukocytosis and elevated serum creatinine. Computed tomography identified a dilated small-bowel loop adjacent to the pancreatic allograft with pneumatosis and free fluid. Emergency exploratory laparotomy revealed necrosis of the graft duodenum and a severely dilated jejunal segment, which was separated from the graft. The abdomen was temporarily closed to allow bowel demarcation. On re-exploration, most of the graft duodenum and a portion of the pancreatic head were necrotic and were debrided, leaving a viable pancreatic graft remnant. External drainage of pancreatic secretions was established, and bowel continuity was restored. At discharge, the C-peptide level was 1.24 ng/mL, and insulin requirements steadily decreased. The patient achieved insulin independence within four weeks. Five months later, a pancreatic fistula developed and was successfully managed with Roux-en-Y pancreaticojejunostomy at seven months. The patient remained insulin-free for 14 months.This case illustrates that pancreas allograft salvage is feasible despite extensive graft duodenal and partial pancreatic necrosis when graft perfusion and endocrine function are preserved. Staged operative management can maintain graft function and avoid graft pancreatectomy.
- 29 July 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessSuccessful Salvage of a Pancreas Allograft Following Duodenal and Partial Pancreatic Necrosis 21 Years After Simultaneous Pancreas-Kidney Transplantation: A Case Report
Simultaneous pancreas-kidney transplantation is an established treatment for type 1 diabetes mellitus and renal dysfunction. However, pancreatic graft complications frequently require graft pancreatectomy. This report describes successful salvage of a functioning pancreas allograft despite extensive duodenal and partial pancreatic necrosis occurring 21 years after transplantation.A 68-year-old man with a simultaneous pancreas-kidney transplant performed 21 years earlier presented with acute right lower quadrant abdominal pain, nausea, and vomiting. Laboratory evaluation revealed leukocytosis and elevated serum creatinine. Computed tomography identified a dilated small-bowel loop adjacent to the pancreatic allograft with pneumatosis and free fluid. Emergency exploratory laparotomy revealed necrosis of the graft duodenum and a severely dilated jejunal segment, which was separated from the graft. The abdomen was temporarily closed to allow bowel demarcation. On re-exploration, most of the graft duodenum and a portion of the pancreatic head were necrotic and were debrided, leaving a viable pancreatic graft remnant. External drainage of pancreatic secretions was established, and bowel continuity was restored. At discharge, the C-peptide level was 1.24 ng/mL, and insulin requirements steadily decreased. The patient achieved insulin independence within four weeks. Five months later, a pancreatic fistula developed and was successfully managed with Roux-en-Y pancreaticojejunostomy at seven months. The patient remained insulin-free for 14 months.This case illustrates that pancreas allograft salvage is feasible despite extensive graft duodenal and partial pancreatic necrosis when graft perfusion and endocrine function are preserved. Staged operative management can maintain graft function and avoid graft pancreatectomy.
- Open Access
- 1 July 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (7) , e01772
Tacrolimus-Induced Acute Esophageal Necrosis Postorthotopic Liver Transplantation
Acute esophageal necrosis, or “black esophagus,” is a rare but severe condition characterized by circumferential black necrotized esophageal mucosa with an abrupt transition at the gastroesophageal junction. The “two-hit” hypothesis suggests that an initial ischemic insult predisposes the esophageal mucosa to further injury from luminal acid exposure or medications. We present the first documented case of tacrolimus-induced acute esophageal necrosis without preceding hemodynamic instability in a liver transplant recipient, which resolved with discontinuation of tacrolimus and transition to cyclosporin.
- 1 July 2025
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 12 (7) , e01772
Open AccessTacrolimus-Induced Acute Esophageal Necrosis Postorthotopic Liver Transplantation
Acute esophageal necrosis, or “black esophagus,” is a rare but severe condition characterized by circumferential black necrotized esophageal mucosa with an abrupt transition at the gastroesophageal junction. The “two-hit” hypothesis suggests that an initial ischemic insult predisposes the esophageal mucosa to further injury from luminal acid exposure or medications. We present the first documented case of tacrolimus-induced acute esophageal necrosis without preceding hemodynamic instability in a liver transplant recipient, which resolved with discontinuation of tacrolimus and transition to cyclosporin.
- 2 September 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (9) , e15451
Strategy and Outcomes of Cardiac Surgery in Patients With Cirrhosis: Comprehensive Approach With Liver Transplant Program
Background: Cardiac surgery is considered a contraindication in patients with advanced liver cirrhosis (LC) due to increased mortality and morbidity. There are limited data on the treatment strategy and management of this population. We aimed to present our strategy and evaluate the clinical outcome of cardiac surgery in patients with LC.Methods: Our strategy was (i) to list patients for liver transplant (LT) at the time of cardiac surgery; (ii) to maintain high cardiopulmonary bypass (CPB) flow (index up to 3.0 L/min/m2) based on hyper‐dynamic states due to LC; and (iii) to proceed to LT if patients’ liver function deteriorated with an increasing model for end‐stage liver disease Na (MELD‐Na) score after cardiac surgery. Thirteen patients (12 male and 1 female [mean age, 63.0]) with LC who underwent cardiac surgery between 2017 and 2024 were retrospectively analyzed.Results: Six patients were listed for LT. Indications for cardiac surgery included coronary artery disease (N = 7), endocarditis (N = 2), and tricuspid regurgitation (N = 1), tricuspid stenosis (N = 1), mitral regurgitation (N = 1), and hypertrophic obstructive cardiomyopathy (N = 1). The Child–Pugh score was A in five, B in six, and C in one patient. The procedure included coronary artery bypass grafting (N = 6), single valve surgery (mitral valve [N = 2] and tricuspid valve [N = 1]), concomitant aortic and tricuspid valve surgery (N = 2), and septal myectomy (N = 1). Two patients had a history of previous sternotomy. The perfusion index during CPB was 3.1 ± 0.5 L/min/m2. Postoperative complications include pleural effusion (N = 6), bleeding events (N = 3), acute kidney injury (N = 1), respiratory failure requiring tracheostomy (N = 2), tamponade (N = 1), and sternal infection (N = 1). There was no in‐hospital death. There was one remote death due to COVID‐19 complication. Preoperative and postoperative highest MELD‐Na score among listed patients was 15.8 ± 5.1 and 19.3 ± 5.3, respectively. Five patients underwent LT (1, 5, 8, 16, and 24 months following cardiac surgery) and one patient remains on the list. Survival rates at 1 and 3 years are 100% and 75.0%, respectively.Conclusion: Cardiac surgery maintaining high CPB flow with LT backup is a feasible strategy in an otherwise inoperable patient population with an acceptable early and midterm survival when performed in a center with an experienced cardiac surgery and LT program.
- 2 September 2024
- Published by Wiley in Clinical Transplantation
- Vol. 38 (9) , e15451
Strategy and Outcomes of Cardiac Surgery in Patients With Cirrhosis: Comprehensive Approach With Liver Transplant Program
Background: Cardiac surgery is considered a contraindication in patients with advanced liver cirrhosis (LC) due to increased mortality and morbidity. There are limited data on the treatment strategy and management of this population. We aimed to present our strategy and evaluate the clinical outcome of cardiac surgery in patients with LC.Methods: Our strategy was (i) to list patients for liver transplant (LT) at the time of cardiac surgery; (ii) to maintain high cardiopulmonary bypass (CPB) flow (index up to 3.0 L/min/m2) based on hyper‐dynamic states due to LC; and (iii) to proceed to LT if patients’ liver function deteriorated with an increasing model for end‐stage liver disease Na (MELD‐Na) score after cardiac surgery. Thirteen patients (12 male and 1 female [mean age, 63.0]) with LC who underwent cardiac surgery between 2017 and 2024 were retrospectively analyzed.Results: Six patients were listed for LT. Indications for cardiac surgery included coronary artery disease (N = 7), endocarditis (N = 2), and tricuspid regurgitation (N = 1), tricuspid stenosis (N = 1), mitral regurgitation (N = 1), and hypertrophic obstructive cardiomyopathy (N = 1). The Child–Pugh score was A in five, B in six, and C in one patient. The procedure included coronary artery bypass grafting (N = 6), single valve surgery (mitral valve [N = 2] and tricuspid valve [N = 1]), concomitant aortic and tricuspid valve surgery (N = 2), and septal myectomy (N = 1). Two patients had a history of previous sternotomy. The perfusion index during CPB was 3.1 ± 0.5 L/min/m2. Postoperative complications include pleural effusion (N = 6), bleeding events (N = 3), acute kidney injury (N = 1), respiratory failure requiring tracheostomy (N = 2), tamponade (N = 1), and sternal infection (N = 1). There was no in‐hospital death. There was one remote death due to COVID‐19 complication. Preoperative and postoperative highest MELD‐Na score among listed patients was 15.8 ± 5.1 and 19.3 ± 5.3, respectively. Five patients underwent LT (1, 5, 8, 16, and 24 months following cardiac surgery) and one patient remains on the list. Survival rates at 1 and 3 years are 100% and 75.0%, respectively.Conclusion: Cardiac surgery maintaining high CPB flow with LT backup is a feasible strategy in an otherwise inoperable patient population with an acceptable early and midterm survival when performed in a center with an experienced cardiac surgery and LT program.
- Open Access
- 5 July 2024
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 10 (8) , e1679
Normothermic Machine Perfusion Is Associated With Improvement in Mortality and Graft Failure in Donation After Cardiac Death Liver Transplant Recipients in the United States
Background.: Use of normothermic machine perfusion (NMP) may help to expand the liver transplantation (LT) donor pool by potentially increasing the utilization of donation after circulatory death (DCD) organs. The aim of this study was to assess the impact of NMP on LT from DCD organs. Methods.: Data among DCD adult LT recipients in the United Network for Organ Sharing between January 2016 and December 2022 were analyzed. Outcomes were compared between 2 groups: NMP versus non-MP using propensity score matching. Results.: During the study period, 4217 DCD LT recipients (NMP: 257 and non-MP: 3960) were identified. compared with non-MP, DCD LT recipients in NMP group were older (median recipient age: 61 versus 59 y, P = 0.013), had lower model for the end-stage liver disease score, longer wait time (126 versus 107 d, P = 0.028), and received organs from older donors (median age: 42 versus 38 y, P < 0.01) with longer preservation time (9.9 versus 5.3 h, P < 0.001). Two-year overall survival (NMP 94.4% versus non-MP 89.7%, P = 0.040) and 2-y graft survival (NMP 91.3% versus non-MP 84.6%, P = 0.017) were better in the NMP group. After propensity score matching, 2-y overall survival (NMP 94.2% versus non-MP 88.0%, P = 0.023) and graft survival (NMP 91.3% versus non-MP 81.6%, P = 0.004) were better in the NMP group. On multivariable cox regression analysis, NMP was an independent factor of protection against mortality (hazard ratio, 0.43; 95% confidence interval: 0.20-0.91; P = 0.029) and against graft failure (hazard ratio, 0.26; 95% confidence interval: 0.11-0.61; P = 0.002). Conclusions.: Use of NMP for LT from DCD donors was associated with improved posttransplant patient and graft survival.
- 5 July 2024
- Published by Wolters Kluwer Health in Transplantation Direct
- Vol. 10 (8) , e1679
Open AccessNormothermic Machine Perfusion Is Associated With Improvement in Mortality and Graft Failure in Donation After Cardiac Death Liver Transplant Recipients in the United States
Background.: Use of normothermic machine perfusion (NMP) may help to expand the liver transplantation (LT) donor pool by potentially increasing the utilization of donation after circulatory death (DCD) organs. The aim of this study was to assess the impact of NMP on LT from DCD organs. Methods.: Data among DCD adult LT recipients in the United Network for Organ Sharing between January 2016 and December 2022 were analyzed. Outcomes were compared between 2 groups: NMP versus non-MP using propensity score matching. Results.: During the study period, 4217 DCD LT recipients (NMP: 257 and non-MP: 3960) were identified. compared with non-MP, DCD LT recipients in NMP group were older (median recipient age: 61 versus 59 y, P = 0.013), had lower model for the end-stage liver disease score, longer wait time (126 versus 107 d, P = 0.028), and received organs from older donors (median age: 42 versus 38 y, P < 0.01) with longer preservation time (9.9 versus 5.3 h, P < 0.001). Two-year overall survival (NMP 94.4% versus non-MP 89.7%, P = 0.040) and 2-y graft survival (NMP 91.3% versus non-MP 84.6%, P = 0.017) were better in the NMP group. After propensity score matching, 2-y overall survival (NMP 94.2% versus non-MP 88.0%, P = 0.023) and graft survival (NMP 91.3% versus non-MP 81.6%, P = 0.004) were better in the NMP group. On multivariable cox regression analysis, NMP was an independent factor of protection against mortality (hazard ratio, 0.43; 95% confidence interval: 0.20-0.91; P = 0.029) and against graft failure (hazard ratio, 0.26; 95% confidence interval: 0.11-0.61; P = 0.002). Conclusions.: Use of NMP for LT from DCD donors was associated with improved posttransplant patient and graft survival.
- 14 June 2024
- Published by Elsevier in Journal of Surgical Research
- Vol. 300, 477-484
Potential Association of Blood Transfusion in Deceased Donors With Outcomes of Liver Transplantation in the United States
- 14 June 2024
- Published by Elsevier in Journal of Surgical Research
- Vol. 300, 477-484
Potential Association of Blood Transfusion in Deceased Donors With Outcomes of Liver Transplantation in the United States
- Open Access
- 12 February 2024
- Published by Elsevier in Journal of Liver Transplantation
- Vol. 14
Use of 50 years or older donors in septuagenarian recipients for liver transplantation: Potential to expand the donor pool
- 12 February 2024
- Published by Elsevier in Journal of Liver Transplantation
- Vol. 14
Open AccessUse of 50 years or older donors in septuagenarian recipients for liver transplantation: Potential to expand the donor pool
- Open Access
- 10 February 2024
- Published by Elsevier in Journal of Liver Transplantation
- Vol. 14
Oral antiviral therapy for treatment of COVID-19 in solid organ transplant recipients: Is the practice meeting the promise?
- 10 February 2024
- Published by Elsevier in Journal of Liver Transplantation
- Vol. 14
Open AccessOral antiviral therapy for treatment of COVID-19 in solid organ transplant recipients: Is the practice meeting the promise?
- Open Access
- 25 January 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (2) , 252-261
High Rate of Kidney Graft Failure after Simultaneous Heart–Kidney Transplantation
Key Points: Simultaneous heart–kidney transplant is associated with high rates of kidney graft failure which are worse when compared with kidney transplant alone. The major causes of kidney graft failure in simultaneous heart–kidney transplant recipients were patient death and primary nonfunction of kidney graft. Background: The indications and outcomes of simultaneous heart–kidney transplantation (SHKT) remain suboptimally defined. Risk factors for renal graft failure after SHKT also remain poorly defined. Methods: We analyzed the renal graft outcomes among SHKT recipients using United Network for Organ Sharing database from 2015 to 2020. To evaluate for factors associated with poor renal outcomes, we compared SHKT and kidney transplantation alone recipients using propensity score matching. Results: Among SHKT recipients, the rate of primary nonfunction (PNF) of kidney graft was 3%, the 30-day kidney graft failure rate was 7.0%, and the 30-day post-transplant mortality rate was 4.1%. The incidence of kidney delayed graft function was 27.5%. Kidney graft failure was seen early post-SHKT with most common causes of patient death (43.9%) and PNF of kidney graft (41.5%). One- and 2-year patient survival was 89.2% and 86.5%, and 1- and 2-year freedom from kidney graft failure was 85.4% and 82.7%, respectively. In subgroup analysis of SHKT recipients, use of pretransplant mechanical cardiac support (adjusted odds ratio [aOR], 2.57; P = 0.017), higher calculated panel reactive antibody (aOR, 1.76; P = 0.016), and older donor age per 10 years (aOR, 1.94; P = 0.001) were associated with PNF. Pretransplant extracorporeal membrane oxygenation support was associated with the increased risk of 30-day recipient mortality (aOR, 5.55; P = 0.002). Increased 30-day graft failure was seen in SHKT recipients with pretransplant mechanical cardiac support (aOR, 1.77; P = 0.038) and dialysis at the time of transplant (aOR, 1.72; P = 0.044). Multivariable Cox hazard analysis demonstrated that SHKT, when compared with kidney transplantation alone, is associated with increased kidney graft failure (hazard ratio, 2.56; P < 0.001) and recipient mortality (hazard ratio, 2.65; P < 0.001). Conclusions: SHKT is associated with high rates of kidney graft failure. Identification of risk factors of renal graft failure can help optimize recipient selection for SHKT versus kidney after heart transplantation, especially after introduction of the new safety-net policy.
- 25 January 2024
- Published by Wolters Kluwer Health in Kidney360
- Vol. 5 (2) , 252-261
Open AccessHigh Rate of Kidney Graft Failure after Simultaneous Heart–Kidney Transplantation
Key Points: Simultaneous heart–kidney transplant is associated with high rates of kidney graft failure which are worse when compared with kidney transplant alone. The major causes of kidney graft failure in simultaneous heart–kidney transplant recipients were patient death and primary nonfunction of kidney graft. Background: The indications and outcomes of simultaneous heart–kidney transplantation (SHKT) remain suboptimally defined. Risk factors for renal graft failure after SHKT also remain poorly defined. Methods: We analyzed the renal graft outcomes among SHKT recipients using United Network for Organ Sharing database from 2015 to 2020. To evaluate for factors associated with poor renal outcomes, we compared SHKT and kidney transplantation alone recipients using propensity score matching. Results: Among SHKT recipients, the rate of primary nonfunction (PNF) of kidney graft was 3%, the 30-day kidney graft failure rate was 7.0%, and the 30-day post-transplant mortality rate was 4.1%. The incidence of kidney delayed graft function was 27.5%. Kidney graft failure was seen early post-SHKT with most common causes of patient death (43.9%) and PNF of kidney graft (41.5%). One- and 2-year patient survival was 89.2% and 86.5%, and 1- and 2-year freedom from kidney graft failure was 85.4% and 82.7%, respectively. In subgroup analysis of SHKT recipients, use of pretransplant mechanical cardiac support (adjusted odds ratio [aOR], 2.57; P = 0.017), higher calculated panel reactive antibody (aOR, 1.76; P = 0.016), and older donor age per 10 years (aOR, 1.94; P = 0.001) were associated with PNF. Pretransplant extracorporeal membrane oxygenation support was associated with the increased risk of 30-day recipient mortality (aOR, 5.55; P = 0.002). Increased 30-day graft failure was seen in SHKT recipients with pretransplant mechanical cardiac support (aOR, 1.77; P = 0.038) and dialysis at the time of transplant (aOR, 1.72; P = 0.044). Multivariable Cox hazard analysis demonstrated that SHKT, when compared with kidney transplantation alone, is associated with increased kidney graft failure (hazard ratio, 2.56; P < 0.001) and recipient mortality (hazard ratio, 2.65; P < 0.001). Conclusions: SHKT is associated with high rates of kidney graft failure. Identification of risk factors of renal graft failure can help optimize recipient selection for SHKT versus kidney after heart transplantation, especially after introduction of the new safety-net policy.
- Open Access
- 31 December 2023
- Published by Elsevier in Journal of Liver Transplantation
- Vol. 13
High discordance rate between explant and listing diagnosis among liver transplant recipients for alcoholic liver disease
- 31 December 2023
- Published by Elsevier in Journal of Liver Transplantation
- Vol. 13
Open AccessHigh discordance rate between explant and listing diagnosis among liver transplant recipients for alcoholic liver disease
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
1350. Solid Organ Transplantation From COVID Positive Donors: Trends in Utilization, Discard & Long-term Outcomes in the United States
Transplantation of organs from COVID positive (COVID+) donors is increasing. The aim of this study was to assess the trends in utilization, discard, and longer-term outcomes in solid organ transplant (SOT) recipients who received organs from COVID+ donors in the United States (US). Rates of utilization, discard, and outcomes of SOT from deceased donors with a positive COVID PCR test from respiratory tract between March 2020 and December 2022 were analyzed using the de-identified United Network for Organ Sharing (UNOS) database. During the study period, 1185 COVID+ donors led to the transplantation of 1249 kidneys, 592 livers, and 168 hearts. The center-wise acceptance rate for organs from COVID+ donors increased from 2021 to 2022: heart from 31% to 73%, kidney from 53% to 88%, and liver from 53% to 89%. Discard rates of kidneys from COVID+ donors remained high: left kidney- 29%, right kidney- 32% and were significantly higher than kidney discard rates for COVID negative (COVID-) donors (p < 0.001) Characteristics and outcomes of solid organ transplantation from COVID+ and COVID- donors Utilization of organs from COVID+ donors has improved across various transplant centers in the US. Kidney discard rate from COVID+ donors remain high. Longer-term outcomes of SOT from COVID+ donors are encouraging and are helping to successfully expand the donor pool. All Authors: No reported disclosures
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access1350. Solid Organ Transplantation From COVID Positive Donors: Trends in Utilization, Discard & Long-term Outcomes in the United States
Transplantation of organs from COVID positive (COVID+) donors is increasing. The aim of this study was to assess the trends in utilization, discard, and longer-term outcomes in solid organ transplant (SOT) recipients who received organs from COVID+ donors in the United States (US). Rates of utilization, discard, and outcomes of SOT from deceased donors with a positive COVID PCR test from respiratory tract between March 2020 and December 2022 were analyzed using the de-identified United Network for Organ Sharing (UNOS) database. During the study period, 1185 COVID+ donors led to the transplantation of 1249 kidneys, 592 livers, and 168 hearts. The center-wise acceptance rate for organs from COVID+ donors increased from 2021 to 2022: heart from 31% to 73%, kidney from 53% to 88%, and liver from 53% to 89%. Discard rates of kidneys from COVID+ donors remained high: left kidney- 29%, right kidney- 32% and were significantly higher than kidney discard rates for COVID negative (COVID-) donors (p < 0.001) Characteristics and outcomes of solid organ transplantation from COVID+ and COVID- donors Utilization of organs from COVID+ donors has improved across various transplant centers in the US. Kidney discard rate from COVID+ donors remain high. Longer-term outcomes of SOT from COVID+ donors are encouraging and are helping to successfully expand the donor pool. All Authors: No reported disclosures